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Hematopoietic inhibitors in chronic renal failure: Lack of in vitro
specificity. To assess the potential role of retained inhibitors in the
pathogenesis of the anemia of chronic renal failure, we have studied
simultaneously the effects of increasing concentrations of normal or
uremic sera on the growth of erythroid colonies (from CFU-E), granu-
locyte-macrophage colonies (from CFU-GM), and megakaryocytic col-
onies (from CFU-Meg) in mouse marrow cell cultures. As compared to
normal human serum, increasing concentrations of uremic sera induced
a dose-dependent inhibition in the growth of all colony types. Signifi-
cant correlations (P < 0.001) were found between the ability of any
individual uremic serum to support CFU-E, CFU-GM, and CFU-Meg
growth, and, whenever significant inhibition was seen, all three progen-
itor types were affected. The inhibitory effect on CFU-E growth was
significantly greater (P < 0.01) in patients with serum creatinine
concentrations  7 mgldl, but no correlation was found between
CFU-E inhibition and hematocrit. Likewise, inhibition of CFU-GM and
CFU-Meg growth was not associated with leukopenia or thrombocyto-
penia, respectively. Sera from patients undergoing chronic intermittent
hemodialysis were assayed before and after one hemodialysis session.
In each case, the degree of inhibition of CFU-E and CFU-GM growth
decreased after hemodialysis, but improvement in CFU-Meg growth
was more variable. These data indicate that uremic sera contain
dialyzable inhibitors of in vitro hematopoiesis which increase with the
severity of renal dysfunction, but these inhibitors lack specificity. If
uremic inhibitors of erythropoiesis are of pathophysiologic significance
in vivo, there must be unrecognized repair mechanisms for granulopoi-
esis and thrombopoiesis.
Numerous studies indicate that inadequate erythropoietin
(Ep) production [1—31 and a shortened red cell survival [4, 5]
contribute to the anemia associated with chronic renal failure
(CRF). In addition, inhibitors of erythropoiesis in CRF have
been suggested to be important in the pathogenesis of anemia
[3, 6—11]. However, such studies are less definitive and have
been plagued by several problems. First, in several reports, the
argument for the presence of an inhibitor has been based on
decreased in vitro erythropoiesis in the presence of uremic sera
as compared to normal sera. However, erythroid cell prolifer-
ation in vitro is modulated by undefined stimulators, as well as
potential inhibitors. Consequently, the findings with uremic
sera could reflect a deficiency of stimulators or the presence of
inhibitors. Other early studies, in which radioactive iron incor-
poration into hemoglobin was used as the endpoint of the assay,
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failed to account for differences in iron pools between test sera
and control sera [12, 13]. Finally, concurrent controls have not
been performed on the same target tissue to determine the
lineage specificity of potential inhibitors of erythropoiesis.
In the experiments reported here, uremic sera exerted a
similar dose-dependent inhibitory effect on erythroid, granulo-
cyte-macrophage, and megakaryocytic colony formation in
murine bone marrow cultures. The degree of inhibition of in
vitro erythroid colony formation significantly correlated with
the severity of the renal insufficiency, but not with the hema-
tocrit. For each serum tested, the inhibitory effect on both
CFU-E— and CFU-GM--derived colony growth decreased after
hemodialysis.
Methods
Study population. Studies involving human subjects were in
accordance with the Declaration of Helsinki and were approved
by the University of Washington Human Subjects Review
Committee. After informed consent, blood samples were taken
from 16 volunteers and 53 patients with CRF who had not been
transfused within the preceding four weeks. Patients on chronic
intermittent hemodialysis were dialyzed for three hours, three
times a week with machines using Travenol dialysis membranes.
Serum preparation. After the blood was allowed to clot at
room temperature for two hours, each sample was centrifuged
at 2000 g for 15 mm. The serum was then removed and heated
at 56°C for 45 mm. Each serum sample was then sterilized by
passage through a 0.45 Millipore filter (Millipore Corporation,
Bedford, Massachusetts, USA) and stored at —70°C until used.
Marrow cells. Marrow cells were obtained from six-week old
female LAF1 mice (Jackson Laboratories, Bar Harbor, Maine,
USA) by flushing the femoral shafts with alpha medium (Flow
Laboratories, Rockville, Maryland, USA) supplemented with
2% fetal calf serum (FCS; Gibco Laboratories, Grand Island,
New York, USA).
Erythroid colony assay
A modification of the methylcellulose technique of Iscove et
al [14] was used for CFU-E. The culture medium, containing
alpha medium, 1% bovine serum albumin (Sigma Chemical Co.,
St. Louis, Missouri, USA), iO M beta-mercaptoethanol, 20
mg!ml streptomycin, 20 units/ml penicillin, and various concen-
trations of FCS and human serum, was made semi-solid with
1% methylcellulose (Eastman Kodak Co., Rochester, New
York, USA). Marrow cells were plated at i05 cells/ml in 35 mm
641
642 Delwiche et al
plastic tissue culture dishes (Lux, Miles Laboratories, Naper-
yule, Illinois, USA) and cultured in the presence of a
suboptimal concentration (0.05 unit/mi) of partially purified
human urinary Ep.
The Ep used in these studies was partially purified from the
urine of a patient with pure red cell aplasia by a four-step
procedure, including ion exchange and concanavalin A chro-
matography [14]. The final preparation had an activity of
approximately 500 units/mg of protein and contained virtually
no granulocyte-macrophage colony-stimulating activity or
erythroid burst-promoting activity.
Cultures were incubated at 37°C in a high-humidity, 5%
COr95% air tissue culture incubator for two days. Aggregates
of eight or more hemoglobinized cells were scored as CFU-
E—derived colonies using a Leitz Diavert inverted microscope
(Leitz, West Germany).
Granulocyte-macrophage colony assay
CPU-GM were assayed in alpha medium with 1%
methylcellulose containing varying concentrations of human
serum and FCS, 1% BSA, and streptomycin and penicillin.
Colony growth was stimulated by a suboptimal (1%) concentra-
tion of PFIA-stimulated LBRM-33 cell line-conditioned medium
prepared as described previously [15j. Cells were plated at
l05/ml and incubated for seven days. Aggregates of forty or
more cells were scored as colonies.
Megakaryocyte colony assay
CPU-Meg were assayed in alpha medium with 1%
methylcellulose containing various concentrations of human
serum and FCS, streptomycin and penicillin, and 5 x i0 M
beta-mercaptoethanol. Colony growth was stimulated by a
suboptimal concentration (5%) of PWM-stimulated murine
spleen cell-conditioned medium prepared as described previ-
ously, except that FCS was substituted for human plasma [16].
Marrow cells were plated at 105/ml and incubated as above.
Megakaryocytic colonies were identified by inverted micros-
copy as aggregates of two or more cells with characteristic
refractile cell membranes and translucent agranular cytoplasm.
Colonies were counted on day five of culture. In preliminary
experiments, staining of the cultures for the megakaryocyte-
specific enzyme acetylcholinesterase [17] confirmed the accu-
racy of scoring these colonies by morphology alone. Granulo-
cyte-macrophage colonies were also enumerated in the same
culture dishes on day seven.
Data analysis
Fifty-one human sera (Group 1) from 43 patients with CRF
and eight normal control subjects were tested simultaneously
for their effect on CFU-E and CFU-GM growth. Eighteen
human sera (Group 2) from ten dialyzed patients with CRF and
eight normal control subjects were tested simultaneously on
CFU-Meg and CPU-GM growth. The data are based on exper-
iments performed in triplicate. Statistical analysis of the rela-
tionship between creatinine and hematocrit levels and between
CFU-E, CPU-GM, and CPU-Meg growth was performed by
the Pearson Product-Moment Correlation Test. Significance
levels of differences between groups of patients with greater or
lesser degrees of renal insufficiency (Pig. 1) and anemia (Pig. 2)
were calculated with the two-sided Wilcoxon Rank Sum Test.
The P values for changes occurring with hemodialysis were
obtained from the P test for treatment effect of a repeated
measures design (Fig. 3—5).
For each experiment, the data were expressed as percent of
control colony growth. Por Group 1 sera, percent control was
defined as the ratio between the numbers of CPU-E— or
CPU-GM—derived colonies grown in 10% PCS plus test serum
compared with colony numbers in the same total volume of
FCS alone:
Number of Colonies in
10% PCS + X% Test Serum
x 100
Number of Colonies in
(10 + X) % FCS
Por Group 2 sera, percent control was taken as the ratio
between the number of CFU-Meg— or CPU-GM-derived colo-
nies grown in 5% FCS plus test serum compared with the
number of colonies in the same total volume of PCS alone:
Number of Colonies in
% Control 5% PCS + X% Test Serum
Colony Growth Number of Colonies in
(5 + X) % FCS
Plating efficiencies for CFU-E, CPU-GM, and CPU-Meg in
various concentrations of PCS are given in Table 1.
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Fig. 1. The in vitro effects on CFU—E growth of sera from 50 patients
with CRF. The patients were divided into those with creatinines S 7
mg/dl (left, n = 12) and those with creatinines > 7 mg/dl (right, n = 38).
At a 5% concentration of test serum, the difference between the two
groups was significant (P C 0.02).
% Control =
Colony Growth
x 100
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Fig. 2. The in vitro effects on CFU-E growth of sera from 31 patients
with CRF. The patients were divided into those with hematocrits  35%
(left, n = 14) and those with hematocrits 25% (right, n = 17). At a 5%
concentration of test serum, the difference between the two groups was
not statistically significant (P > 0.05).
Results
Fig. 6 shows the relationship between hematocrit and creatinine
for 51 patients with CRF. The correlation coefficient was —0.58
and was statistically significant (P = 0.02). For dialysis patients,
the values shown represent pre-dialysis measurements.
Effect of normal or uremic sera on CFU-E growth (Fig. 7).
Various concentrations of eight normal human sera and sera
from 43 patients with CRF were tested on mouse CFU-E
growth. In cultures with 5% normal human serum plus 10%
FCS, the number of erythroid colonies always exceeded the
number obtained in 15% FCS alone. In contrast, 5% uremic
serum supported CFU-E growth significantly less well than
normal serum. Increasing concentrations of test sera induced a
dose-dependent inhibition of CFU-E growth with almost no
growth at 15% uremic serum.
Effect of normal or uremic sera on CF U-GM growth (Fig. 8).
Normal human serum at concentrations of 5, 10 and 15 percent
supported increased granulocyte-macrophage colony growth
relative to control. A dose-dependent inhibition of CFU-GM
growth was observed with increasing concentrations of uremic
sera.
Correlation between the effects of uremic sera on CFU-E and
CFU-GM growth. When the effects of 5% test serum from 43
patients with CRF were compared with their influence on the
growth of both progenitor types, a significant correlation (P <
Fig. 4. The effect of hemodialysis on the ability of CRF serum to support
in vitro CFU-GM growth. Sera from 11 subjects were tested at a
concentration of 5%. The ability of post-dialysis serum to support
CFU—GM growth was significantly increased (P < 0.005).
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Fig. 3. The effect of hemodialysis on the ability of CRF serum to support
in vitro CFU—E growth. Sera from 11 subjects were tested at a
concentration of 5%. The ability of the post-dialysis sera to support
CFU—E growth was significantly (P < 0.001) increased.
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0.001) was found (Fig. 9), The same significant correlation was
found in experiments using 10 percent serum concentration
(data not shown).
Effect of normal or uremic sera on CFU-Meg growth. Vari-
ous concentrations of sera from eight normal controls and
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Fig. 5. The effect of hemodialysis on the ability of CRF serum to support
in vitro CPU—Meg growth, Sera from six patients were tested at a 5%
concentration. In four instances, CFU—Meg growth was supported
better by post-dialysis sera, while in two instances, there was little or no
change. The difference between the pre— and post—dialysis values for
the group failed to reach statistical significance (P = 0.10).
FCS Concentration
10% 15% 20% 25%
Group
CFU-E 89 12* 139 19 164 10 NDt
CFU-GM 45 1 53 3 62 4 NDt
Group 2
CFU-Meg 7.3 4 10.3 1.2 11.7 0.9 11.7 1.5
CPU-GM 121 4 147 3 163 4 154
Thenumbers of colonies are expressed per l0 marrow cells plated.
Values shown are the mean SEM of experiments performed in
triplicate. At least three plates were used in each of the three separate
experiments.
t ND = Not done.
pre-dialysis sera from 10 patients with CRF were tested for their
effect on mouse CFU-Meg growth (Fig. 10). Normal human
serum was superior or equal to equivalent concentrations of
FCS in supporting megakaryocytic colony growth. The uremic
sera were inhibitory.
Similar to the results shown in Fig. 8, granulocyte-macro-
phage colony growth, assessed simultaneously in these cul-
tures, was stimulated by normal human serum and inhibited by
uremic serum (data not shown). There was a significant corre-
lation (P C 0.001) between the ability of each uremic serum at
5 percent concentration to support CFU-Meg— and CFU-
GM—derived colony growth (Fig. 11).
Correlation between in vitro inhibition of erythroid progeni-
tor growth and the severity of renal insufficiency and anemia.
The results with fifty uremic sera were separated into two
groups on the basis of serum creatinine values (Fig. 1). In the
group with a creatinine level  7 mg/dl, enhancement of CFU-E
growth was seen with 9 of 12 samples. Activity ranging widely
from stimulation to complete inhibition was seen with sera from
38 patients whose creatinine exceeded 7 mg/dl. The difference
between the two groups was significant (P < 0.02). Similarly,
sera from patients whose hematocrits were  25% supported
CFU-E growth less well than did sera from patients whose
hematocrits were  35%, although the difference did not
achieve statistical significance (0.10 > P > 0.05) (Fig. 2). This
trend was lost completely at 10% serum concentration (data not
shown). No significant correlation was found between CFU-
Meg— or CFU-GM—derived colony growth and creatinine, hem-
atocrit, white blood cell count or platelet count.
Effects of hemodialysis on the in vitro inhibitory effect of
uremic sera. Sera from 11 patients were obtained before and
after hemodialysis. In each case, a significant increase in the
ability of 5% serum to support CFU-E growth was seen after
dialysis (Fig. 3). Four of these sera completely inhibited CFU-E
growth prior to dialysis but enhanced growth following dialysis.
Comparable results for CFU-GM were obtained with the same
sera (Fig. 4). All samples either became less inhibitory or
actually enhanced CFU-GM growth following dialysis.
The effects of pre- and post-dialysis serum samples on
CFU-Meg—derived colony growth are shown in Figure 5. At 5%
concentration, four of the six sera tested supported increased
megakaryocytic colony growth after dialysis. However, the
difference between pre- and post-dialysis values did not reach
statistical significance for the group as a whole (P =0.10).
Discussion
Anemia is almost universally encountered in patients with
advanced CRF. Although shortened red cell survival has been
demonstrated [4, Si, the major cause of anemia is decreased red
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Table 1. Plating efficiencies for progenitor cell growth
in control cultures
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Fig. 7. The effect of increasing concentrations of normal (solid line) or
uremic (broken line) sera on CFU-E-derived colony growth. In this and
subsequent figures, the data are expressed as the percentage of colonies
observed in test serum compared with controls grown in the same final
concentration of FCS alone. Each data point represents the mean (±
SEM) of 8 normal human sera or 43 uremic sera.
blood cell production. Myelofibrosis may contribute to im-
paired erythropoiesis in a few cases [18]. However, in the
majority of patients, impaired renal secretion of Ep appears to
be the most important factor. Nevertheless, some patients
demonstrate normal or increased plasma Ep levels as deter-
mined by biological [19] or immunological [11, 20, 21] assays.
Such observations have led to the concept that, at least in some
patients, erythropoietic tissue is less sensitive to Ep. Uremic
toxins, which accumulate in the plasma of patients with CRF,
might interfere with the metabolic events which follow the
interaction of Ep with its target cells. The existence of such
erythropoietic inhibitors was suggested by the data of Eschbach
et al [22] who noted increased erythropoietic activity following
the institution of chronic hemodialysis in four of five patients
with end-stage renal disease. However, most of the studies of
possible inhibitors of erythropoiesis have been performed in
vitro and have not directly addressed the question of in vivo
relevance [9], In most in vitro studies, decreased erythroid
colony formation or radioactive iron incorporation into heme in
the presence of uremic serum has been interpreted as inhibition,
but such effects could also result from a lack of stimulatory
factors in uremic sera. Therefore, we studied various concen-
trations of normal or uremic sera and found for both a dose-
dependent inhibition of erythroid colony formation. Even as
uremic sera inhibit CFU-E growth, normal human sera also
contain inhibitors, but to a lesser degree. Chan et al [23] have
also found dialyzable and heat-labile inhibitors of in vitro
murine granulocyte-macrophage colony formation in normal
human serum.
Anemia is the most common hematologic abnormality in
CRF; leukopenia and thrombocytopenia are not usually ob-
served. Consequently, most studies of inhibitors in CRF have
focused on the effect of uremic serum on erythropoiesis without
concurrent studies of granulopoiesis and thrombopoiesis. Only
the studies of Vincent et al [24] and McGonigle et a! [11] have
examined granulopoiesis in vitro, and divergent results were
obtained. In the former, CRF sera inhibited CFU-GM growth,
apparently by interfering with release of colony-stimulating
factor. McGonigle found no inhibitory effect of CRF sera on
human CFU-GM growth. However, no studies have examined
simultaneously the effect of CRF sera on erythroid and a
spectrum of non-erythroid progenitors. Although patients in our
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Fig. 9. The reltionship between the effect of 43 uremic sera on CFU—E
and CFU—GM growth in the presence of 5% serum concentration. A
significant (P C 0.001) linear correlation was found. Data are expressed
as percent of controls cultured in the same final concentration of FCS
alone. (R = 0.58)
study did not have leukopenia or thrombocytopenia, we inves-
tigated the effects of normal and uremic sera on in vitro
granulopoiesis and megakaryopoiesis, as well as erythropoiesis.
To avoid inhibition which might result from transfusion-related
allosensitization, or inhibition due to genetic differences, we
employed a xenogeneic target for our studies, similar to the
strategy originally used by Wallner and Vautrin 19]. The results
indicated that uremic sera, more than normal sera, inhibited in
vitro colony growth from all progenitor types. The similar
dose-dependent inhibition of CFU-GM and CFU-Meg growth
with increasing concentrations of uremic sera, and the signifi-
cant correlation found between the effects of these sera on all
three progenitor types, demonstrate a lack of in vitro specificity
of such inhibitors. This is consistent with previous studies
which reported impaired cell proliferation in CRF in a variety of
tissues including intestinal epithelium [25], granulation tissue
[26], lymphocytes [27], and male germinal epithelium [28].
Candidate inhibitors of erythropoiesis have been described.
Spermine has been shown convincingly to inhibit in vitro
erythropoiesis by Radtke et al [29] but the issue of specificity
was not addressed. Caro and Erslev have provided recent data
demonstrating that spermine also inhibits in vitro granulopoie-
sis [30]. The inhibitory effect of crude parathyroid gland ex-
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Fig. 11. The relationship between the effect of 10 uremic sera on
CFU—Meg and CFU—GM growth in the presence of 5% serum concen-
tration. A significant correlation (P C 0.001) exists. Data are expressed
as percent control colonies growth in the same final concentration of
FCS alone. (R = 0.89)
tracts [31] was also shown to be non-specific, and, in fact,
disappeared when pure parathyroid hormone was tested [32].
Thus, none of the putative inhibitors identified to date has
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demonstrated specificity or even a significant differential effect
on erythropoiesis.
The in vitro inhibitory activity of uremic sera was greatest in
patients with more severe renal dysfunction. This observation
is in accord with the results of Wallner and Vautrin [91 and
McGonigle et a! [11]. However, unlike McGonigle [11], we
found no significant correlation between the degree of in vitro
inhibition and the hematocrit level despite the expected corre-
lation found between hematocrit and creatinine in our patient
population. Although the results achieved near-significance
when inhibitor activity was assessed at a 5% concentration of
test serum, the difference was lost completely (P > 0.50) when
the CRF sera were tested at 10% concentration.
Our results also confirm that the inhibitory activity is dialyz-
able in vivo [331. Since neutropenia and thrombocytopenia are
observed infrequently among chronic dialysis patients, one
might speculate that dialysis is less effective in removing the
erythropoietic inhibitor than inhibitory activity for granulopoi-
esis and megakaryopoiesis. No evidence for such a differential
effect of dialysis was found, however (Fig. 3—5). In fact, the
dialysis appeared to have the most dramatic effect on the
erythropoietic inhibitor (Fig. 3). For almost all of the sera
tested, the non-specific inhibitory effect significantly decreased
and actual stimulation of erythroid and non-erythroid colony
growth was observed with many specimens following dialysis.
This effect was much less obvious using 10% concentrations of
uremic serum (data not shown), suggesting that a single
hemodialysis only partially removed the inhibitory substances.
Whether other forms of dialysis would be more effective as
reflected by these assays remains to be determined.
These results point out the pitfalls in the interpretation of in
vitro growth assays in defining the pathophysiological relevance of
inhibitor substances. Taken at full value, the data support the
conclusion that either these inhibitors as defined in vitro are of
little importance, given their non-specificity, or else there are
repair mechanisms which restore granulopoiesis and megakaryo-
poiesis to normal in the patient. It may well be that such inhibitors
are important in the anemia of CRF. At the present time, however,
their true significance and, more importantly, their predictive
value will not become obvious until trials of Ep replacement
therapy are conducted in man in the same fashion as has been
done in uremic sheep [34] or until strategies are devised which
truly reveal the erythroid-speciflc nature of these inhibitors.
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